logo-loader
RNS
Nuformix PLC

Appointment of Chairman

RNS Number : 9538R
Nuformix PLC
25 August 2026
 

25 August 2026

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Appointment of Chairman

 

Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Tim Metcalfe as Non-Executive Chairman and a Director of the Company with effect from 1 September 2026.

 

Julian Gilbert, the Company's current Non-Executive Chairman, has decided to step down from the Board on 31 August 2026 for personal reasons, but he will remain available to the Company in a consultancy capacity, providing continuity and access to his considerable sector knowledge and experience.

 

Tim is a highly experienced corporate financier and company adviser, having spent over 30 years in a variety of senior City and corporate roles.  He has held senior positions at Robert Fleming, Rothschild, Westhouse Securities, Northland Capital Partners and he was Joint CEO of Zeus Capital, prior to co-founding IFC Advisory, an investor relations and financial PR adviser, in 2015.  During his career, Tim has had a particular focus on advising companies on strategy, M&A, capital markets and regulatory matters.

 

In addition to his role as Managing Director of IFC Advisory, Tim is Senior Independent Non-Executive Director of The Investment Company plc, an investment trust listed on the Main Market of the London Stock Exchange, and Non-Executive Chairman of Equipmake Holdings plc, which is listed on Aquis.  He is also a director of a number of private companies.

 

Dr Julian Gilbert, outgoing Non-Executive Chairman of Nuformix, commented: "I am very pleased that Tim has agreed to become Chairman of Nuformix. I have worked closely with Tim and believe his extensive corporate, capital markets and strategic experience will be highly valuable to the Company as it seeks to maximise the value of its NXP002 programme and considers the opportunities available to it.

 

"I would like to thank our shareholders and the Nuformix team for their support during my time as Chairman and I look forward to continuing to support the Company in a consultancy capacity."

 

Tim Metcalfe, incoming Non-Executive Chairman of Nuformix, commented: "I am delighted to be joining Nuformix as its new Chairman. I look forward to working closely with Dan and the wider team, with a particular focus on creating value for shareholders through the Company's NXP002 programme, ongoing partnering discussions and the consideration of broader strategic opportunities that can enhance the Company's prospects and deliver long-term value."

 

Further information

 

In accordance with UKLR 6.4.8R, Timothy ("Tim") Mark Metcalfe currently holds, or has held during the five years preceding the date of this announcement, the following directorships of publicly quoted companies:

Current: Equipmake Holdings plc; The Investment Company plc

Former: Spiritus Mundi plc

 

There is no further information required to be disclosed pursuant to UKLR 6.4.8R.

 

Enquiries:

 

Nuformix plc

 

Dr Julian Gilbert, Non-Executive Chairman

Dr Dan Gooding, Executive Director

Tim Metcalfe, incoming Non-Executive Chairman

 

Via IFC Advisory

 

CMC Markets


Douglas Crippen

+44 (0) 20 3003 8632



IFC Advisory Limited


Graham Herring

Zach Cohen

+44 (0) 20 3934 6632

nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZLFLQVLFBBK
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read